GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Invitae Corp (OTCPK:NVTAQ) » Definitions » EV-to-EBIT

Invitae (Invitae) EV-to-EBIT : -0.89 (As of May. 07, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Invitae EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Invitae's Enterprise Value is $1,254.2 Mil. Invitae's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-1,416.1 Mil. Therefore, Invitae's EV-to-EBIT for today is -0.89.

The historical rank and industry rank for Invitae's EV-to-EBIT or its related term are showing as below:

NVTAQ' s EV-to-EBIT Range Over the Past 10 Years
Min: -22.26   Med: -3.45   Max: -0.21
Current: -0.89

During the past 11 years, the highest EV-to-EBIT of Invitae was -0.21. The lowest was -22.26. And the median was -3.45.

NVTAQ's EV-to-EBIT is ranked worse than
100% of 106 companies
in the Medical Diagnostics & Research industry
Industry Median: 21.04 vs NVTAQ: -0.89

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Invitae's Enterprise Value for the quarter that ended in Sep. 2023 was $1,427.2 Mil. Invitae's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-1,416.1 Mil. Invitae's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -99.22%.


Invitae EV-to-EBIT Historical Data

The historical data trend for Invitae's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invitae EV-to-EBIT Chart

Invitae Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.29 -6.13 -11.49 -11.37 -0.54

Invitae Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.55 -0.54 -0.52 -2.05 -1.01

Competitive Comparison of Invitae's EV-to-EBIT

For the Diagnostics & Research subindustry, Invitae's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invitae's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Invitae's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Invitae's EV-to-EBIT falls into.



Invitae EV-to-EBIT Calculation

Invitae's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1254.236/-1416.062
=-0.89

Invitae's current Enterprise Value is $1,254.2 Mil.
Invitae's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,416.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Invitae  (OTCPK:NVTAQ) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Invitae's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 ) =EBIT / Enterprise Value (Q: Sep. 2023 )
=-1416.062/1427.1915636
=-99.22 %

Invitae's Enterprise Value for the quarter that ended in Sep. 2023 was $1,427.2 Mil.
Invitae's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,416.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Invitae EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Invitae's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Invitae (Invitae) Business Description

Traded in Other Exchanges
Address
1400 16th Street, San Francisco, CA, USA, 94103
Invitae Corp operates as a genetic information company in diagnostic and research industry. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions.
Executives
Ana J. Schrank officer: Chief Financial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Robert M. Guigley officer: Chief Commercial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Robert Iv Dickey officer: See Remarks 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Jeff Parsons officer: See remarks 2575 AUGUSTINE DRIVE, SANTA CLARA CA 95054
Robert L Nussbaum officer: Chief Medical Officer 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Thomas Brida officer: General Counsel 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Robert F. Werner officer: Chief Accounting Officer 2500 FABER PLACE, PALO ALTO CA 94303
Yafei Wen officer: Chief Financial Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
Kenneth D. Knight officer: Chief Operating Officer 1400 16TH STREET, SAN FRANCISCO CA 94103
William H Osborne director 1415 WEST 22ND STREET, SUITE 1100, OAK BROOK IL 60523
Sean E George director, officer: CEO 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Shelly D Guyer officer: Chief Financial Officer 1025 GREEN STREET, SAN FRANCISCO CA 94133
Katherine Stueland officer: Chief Commercial Officer 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Geoffrey Crouse director 3130 GATEWAY DRIVE, P O BOX 5625, NORCROSS GA 30091-5625
Jason W. Myers director, other: President, Oncology C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301

Invitae (Invitae) Headlines

From GuruFocus

Q1 2022 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Invitae Corp at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 02-14-2024

Q2 2022 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2022 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2021 Invitae Corp Earnings Call Transcript

By GuruFocus Research 02-14-2024

Invitae Corp M&A Call Transcript

By GuruFocus Research 02-14-2024